Table 3 Rates of conversion from normouricemia at initial check to hyperuricemia and from below common treatment goals to above common treatment goals at any subsequent serum urate check
From: Variation in serum urate levels in the absence of gout and urate lowering therapy
Serum urate at screening (mg/dL) | Number of participants | Number of participants converted to > 5 | Number of participants converted to > 6 | Number of participants converted to hyperuricemia (> 6.8 mg/dL) | |||
|---|---|---|---|---|---|---|---|
n | % (95% CI) | n | % (95% CI) | n | % (95% CI) | ||
4.0–4.4 | 11 | 2 | 18% (2–52%) | 0 | (0%) | 0 | (0%) |
4.5–4.9 | 11 | 5 | 45%(17–77%) | 1 | 9%(0.2–41%) | 1 | 9%(0.2–41%) |
5.0–5.4 | 14 | N/A | 6 | 43%(18–71%) | 0 | (0%) | |
5.5–5.9 | 18 | N/A | 14 | 78%(52–94%) | 3 | 17%(4–41%) | |
6.0–6.8 | 18 | N/A | N/A | 7 | 39%(17–64%) | ||
< 5.0 | 22 | 7 | 32%(14–55%) | 1 | 5%(0.1–23%) | 1 | 5%(0.1–23%) |
< 6.0 | 54 | N/A | 21 | 39%(26–53%) | 4 | 7%(2–18%) | |
≤ 6.8 | 72 | N/A | N/A | 15 | 21%(12–32%) | ||